OBJECTIVE: Oral squamous cell carcinoma (OSCC) is the sixth most common human neoplasm worldwide. Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is highly expressed in human OSCC and is a target for cancer therapy and prevention. This study investigated the therapeutic and preventive effects of an inhibitor of EGFR ( PD153035) on OSCC. METHODS: The effects of PD153035 were examined in human cancer cell lines in vitro, in an athymic nude mouse xenograft model in vivo, and in the 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch tumour model in vivo. RESULTS: PD153035 significantly inhibited cell growth, delayed cell cycle progression and induced apoptosis in human OSCC cells in vitro. In vivo, PD153035 inhibited xenograft tumour growth in nude mice in a dose-dependent manner and prevented the development of OSCC at the postinitiation stage in the DMBA-induced hamster cheek pouch tumour model. PD153035 inhibited the DMBA-induced increases in cell proliferation and in levels of phosphorylated EGFR and phosphorylated signal transducer and activator of transcription 3 (STAT3) protein in the hamster cheek pouch. CONCLUSIONS: Inhibitors of EGFR, such as PD153035, have potential value in the treatment and prevention of OSCC.
Introduction
Oral squamous cell carcinoma (OSCC) is the sixth most common human neoplasm worldwide. 1 In the USA, around 36 540 new cases and 7880 deaths were expected in 2010. 2 Despite progress in surgery, chemotherapy, radiotherapy and combinations of treatment modalities, the prognosis for OSCC is poor. The overall 5-year survival rate for oral cancer patients remains around 50%, 3 underscoring the need for novel therapeutic and preventive agents.
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family that is highly expressed in many solid H Ge, H Liu, Z Fu et al. EGFR inhibitor treatment of OSCC tumours, including OSCC. 4, 5 When activated by various ligands, these receptors homo-or heterodimerize with each other to form active tyrosine kinases, and activate various downstream signalling molecules, including mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase and signal transducer and activator of transcription (STAT) proteins. 6 Inhibition of the tyrosine kinase activity of EGFR has been shown to inhibit tumour growth, metastasis and angiogenesis and to promote apoptosis of cancer cells, and it demonstrates a synergistic effect when used with conventional cytotoxic treatment modalities such as radiotherapy and chemotherapy. 7 -10 Several EGFR tyrosine kinase inhibitors have been described. Quinazoline derivatives, such as PD153035 (4-N-(3bromoanilino)-6,7-dimethoxyquinazoline) and gefitinib, were reported to be highly selective and potent in isolated receptor and cell-based assays. 11 This class of inhibitors binds to the adenosine triphosphate (ATP)binding pocket within the tyrosine kinase domain but does not directly block the activity of other ErbB receptors. 12 In addition, they have been shown to inhibit EGFdependent EGFR phosphorylation and to suppress the proliferation of human cancer cells that overexpress the EGFR gene. 13, 14 The present study evaluated the therapeutic and preventive effects of PD153035 on OSCC in vitro and in vivo, using a cell culture model, a xenograft mouse model and the 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch model. 
Materials and methods

CELL LINES AND CULTURE CONDITIONS
CYTOTOXICITY ASSAY
Exponentially growing cells of all six cell lines (KB, KB/V, Hep2, A83, Tca83, Tca8113) were seeded into 96-well plates in a total volume of 100 µl at a density of 2.0 × 10 4 cells/ml. After 24 h, the cells were treated with serial dilutions (0, 1, 5, 10 µmol/l) of PD153035 for 72 h. The cells were then fixed with 10% trichloroacetic acid at 4°C for 1 h, washed five times with distilled water, airdried and stained with sulforhodamine B (100 µl, 0.4% in 1% acetic acid) for 10 min at room temperature. Plates were washed five times with 1% acetic acid to remove excess dye and air-dried. Tris base solution (150 µl, 0.01 mol/l, pH 10.5) was added to each well and the optical density at 515 nm was recorded, at T 0 (i.e. in untreated cells in a separate control plate at the start of the experiment) and after 72 h (T ) of treatment, using a 96-well plate reader (WellScan MK3; Labsystems Dragon, Helsinki, Finland). Each test was performed in triplicate. The 50% growth inhibitory concentration (GI 50 ) was calculated according to the following equation: GI 50 = 100 × (T -T 0 )/(C -T 0 ), where T and T 0 are as described above and C is the optical density at 515 nm in untreated control cells.
CELL CYCLE AND APOPTOSIS ANALYSIS
Exponentially growing KB and KB/V cells (10 ml, 1.0 × 10 5 cells/ml) were seeded in 75-cm 2 culture bottles and incubated with PD153035 (0, 1, 5 and 10 µmol/l) in complete medium (plus 200 ng/ml vinblastine in KB/V cells). After 48 h, cells were collected, washed with cold 0.01 mol/l phosphate-buffered saline (PBS; pH 7.4), and fixed overnight in ice-cold 70% ethanol. Cells were then centrifuged at 223 g for 5 min, washed and resuspended in 0.01 mol/l PBS containing DNase-free RNase (final concentration 60 µg/ml). After 30 min at 37°C, 50 µg/ml propidium iodide was added. Cells were incubated in the dark at 4°C for 60 min, filtered through a 70-µm nylon mesh (BD Falcon TM ; Becton, Dickinson, Franklin Lakes, NJ, USA) to remove cell clusters and analysed by flow cytometry (Coulter ® Epics ® XL™; Beckman Coulter, Miami, FL, USA). Cell subpopulations in G 0 /G 1 , S and G 2 /M phases and apoptotic cells were calculated by gating analysis based on differences in DNA content. At least 20 000 cells were analysed per sample.
TUMOUR XENOGRAFT MODEL
Exponentially growing KB or KB/V cells (1.0 × 10 7 ) suspended in 0.2 ml saline were injected subcutaneously into the right axilla of four female immunodeficient BALB/c nude mice (each cell line was injected into two mice). After the tumour had grown to 1 cm in diameter, mice were sacrificed and the tumour was removed under sterile conditions and cut into 1.0-mm 3 pieces that were then implanted subcutaneously into the right axilla of nude mice (tumour fragments from each of the two cell lines were implanted into 21 mice). The KB and KB/V tumour-bearing mice were divided into three groups (n = 7 per group) 7 days after tumour inoculation. Mice
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were treated with 4 or 8 mg/kg PD153035 or normal saline by intraperitoneal injection (0.2 ml/20 g body weight) once daily for 24 days. Mice were weighed and the tumours were measured with calipers (and tumour volume was calculated) twice a week throughout the duration of the experiment. Relative tumour volume was expressed as the V t /V 0 index, where V t was the tumour volume on the day of measurement and V 0 was the volume of the same tumour at the beginning of treatment. At the end of the experiment, mice were sacrificed and weighed again and tumour volume was recorded. Tumours were then removed and weighed.
DMBA-INDUCED CARCINOGENESIS
After 1 week of acclimatization, hamsters were divided into four groups. Group A (n = 10) was the negative control and received no treatment. The left cheek pouch of the remaining animals (n = 60) was topically treated with 0.5% DMBA in 100 µl of mineral oil using a paintbrush three times a week for 6 weeks. Animals were then divided into three groups of 20 animals. Group B was the positive control and received no further treatment. Groups C and D received 3 or 6 mg/kg PD153035 intraperitoneally, respectively, every other day for 12 weeks. The hamsters were weighed once a week from the first week. Animals were sacrificed at the end of the experiment (week 18), 2 h after 50 mg/kg bromodeoxyuridine (BrdU) intraperitoneal injection. The whole cheek pouch was harvested and flattened on a transparent plate, and the number of visible tumours was counted. The length, width and height of each tumour were measured with calipers, and tumour volume was calculated using the formula: volume = 4/3πr 3 (where r was the mean radius of the three diameter measurements in mm). Afterwards, the whole cheek pouch was divided into two parts: one part was frozen at -80°C for EGFR analysis, and the remainder was fixed in 10% PBS-buffered formalin for histopathology.
HISTOPATHOLOGICAL ANALYSIS
In order to facilitate embedding and microscopy, the formalin-fixed pouches were cut into 4 -6 pieces of approximately equal width, then each pouch piece was wound into a coil, processed and embedded in paraffin. Each sample was cut into 30 sections (5 µm thick), and the first, 15th, and final sections were stained with haematoxylin and eosin for histopathological analysis. Basal cell hyperplasia, dysplasia and OSCC were diagnosed using established criteria. 15
CELL PROLIFERATION ANALYSIS
Immunostaining with BrdU was performed on formalin-fixed, paraffin-embedded hamster cheek pouch tissue sections to assess cell proliferation in the squamous epithelium. Immunohisto chemistry was performed using the UltraSensitive™ S-P kit (Kit-9720; Fujian Maixin Biological Technology Co. Ltd, Fuzhou, China) according to the manufacturer's instructions. Endogenous peroxidase activity was blocked with 50 µl of 3% hydrogen peroxide for 10 min at 37°C. Slides were washed in 0.01 mol/l PBS (pH 7.4) three times for 3 min each wash, then placed in 2 N hydrochloric acid for 30 min at 37°C to denature the DNA. Slides were then washed again, as above, and enzymatic antigen retrieval was carried out by incubation with 100 µl of prewarmed 0.4% (w/v) pepsin solution for 30 min at 37°C. Slides were washed and incubated with 100 µl normal nonimmune goat serum for 15 min at room temperature, followed by 100 µl of mouse monoclonal BrdU antibody 
WESTERN BLOT ANALYSIS OF PHOSPHORYLATED EGFR AND STAT3
Frozen hamster cheek pouches (0.3 g; six randomly selected samples from each group) were homogenized in 2.0 ml radioimmunoprecipitation assay buffer. Tissue debris was removed by centrifugation (13 000 g at 4°C for 15 min), the protein concentration of the supernatants was determined by bicinchoninic acid protein assay kit (GeLen Biopharm Intermational Co. Ltd, Beijing, China), and 50 µg of total protein was subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis before transfer to nitrocellulose membranes. Membranes were blocked with 5% bovine serum albumin for 1 h at room temperature and incubated with the following primary mouse monoclonal antibodies overnight at 4°C: antiphosphorylated-EGFR (Tyr1068; 1H12; pEGFR; 1 : 1000 dilution) and antiphosphorylated-STAT3 (Tyr705; 3E2; pSTAT3; 1 : 1000 dilution) (both from Cell Signaling Technology, Danvers, MA, USA), and anti-β-actin (1 : 3000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were washed three times for 5 min with 0.1% Tween-20 in 1 × Tris-buffered saline (TBST; pH 7.6), incubated for 1 h at room temperature with IRDye ® 800 conjugated affinity purified antimouse immunoglobulin G (H&L) [goat] fluorescent antibody (Cat. No. 610-132-121; 1 : 20 000 dilution; Rockland Immuno chemicals, Gilbertsville, PA, USA) in the dark, and washed with 1 × TBST three times for 10 min each wash. Immunoreactive protein bands were visualized with the LI-COR Odyssey ® system (LI-COR Biosciences, Lincoln, NE, USA) and Quantity One 4.4.0 software (Bio-Rad, Hercules, CA, USA) was used to semiquantify proteins.
STATISTICAL ANALYSES
Statistical analyses were performed using the SPSS ® software package, version 10.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . In vitro cell culture data were obtained from at least three independent experiments and data were expressed as mean ± SD unless otherwise stated. Differences in the cell cycle distribution and rate of apoptosis in treated versus untreated cells were analysed using one-way analysis of variance (ANOVA) and the χ 2 -test, respectively. The incidence of oral lesions in hamsters was analysed with the χ 2test. Body weight, the number of visible tumours in mice and the number of oral lesions in hamsters were compared with oneway ANOVA. Between-group differences in tumour volume were compared using the Wilcoxon signed-rank test. A P-value < 0.05 was considered to be statistically significant.
Results
The mean ± SD GI 50 of PD153035 in KB,
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KB/V, Hep2, A83, Tca83 and Tca8113 cells in vitro was 2.57 ± 0.65, 0.73 ± 0.13, 7.71 ± 0.39, 9.35 ± 0.33, 7.14 ± 0.47 and 10.02 ± 0.28 µmol/l, respectively (Fig. 1A) . KB and KB/V cells were the most responsive to PD153035 treatment and were selected for subsequent experiments.
The EGFR inhibitor PD153035 (5 and 10 µmol/l) induced a significant increase in the percentage of KB cells in G 0 /G 1 phase, with a corresponding significant decrease in the percentage of cells in S and G 2 /M phase, in a dose-dependent manner (P < 0.001; Fig. 1B ). PD153035 (1, 5 and 10 µmol/l) had no significant effect on the percentage of KB/V cells in G 0 /G 1 and S phase but significantly increased the number of cells in the G 2 /M phase compared with controls (P < 0.001; Fig.  1B ). PD153035 increased apoptosis in KB cells (P = 0.038 at 5 µmol/l and P < 0.001 at 10 µmol/l) and KB/V cells (P < 0.001 at 5 and 10 µmol/l) in a dose-dependent manner (Fig.  1C) .
PD153035 inhibited KB-and KB/V-induced tumour growth (tumour volume and weight) in a dose-dependent manner in athymic nude mice (Fig. 2) . Mice bearing KB cell tumours that were treated with PD153035 (4 or 8 mg/kg) showed growth inhibition of 43.4% or 45.6%, respectively, compared with controls. Mice bearing KB/V tumours that were treated with PD153035 (4 or 8 mg/kg) showed growth inhibition of 8.4% or 40.5%, respectively, compared with controls. There were no significant changes in body weight of mice during the experiment (data not shown).
Hamsters appeared healthy throughout the duration of the experiment. Their body weight was monitored once a week and increased steadily, but DMBA-treated animals weighed less than untreated animals by 4 -8% (P = 0.020; data not shown).
Topical application of DMBA for 6 weeks led to the development of oral lesions in the hamster cheek pouch (Table 1) . Treatment with 3 mg/kg PD153035 significantly inhibited the mean number and volume of DMBA-induced visible tumours compared with positive controls (P = 0.034; Table 1 ), but this did not appear to be dose-dependent and PD153035 had no significant effect on the incidence of visible tumours. Microscopic observation showed that PD153035 (3 or 6 mg/kg) significantly reduced the numbers of dysplastic and OSCC lesions compared with positive controls (P < 0.001 for all comparisons; Table 1 ).
Immunostaining with BrdU revealed a significant increase in cell proliferation in the cheek pouch tissue of positive control animals compared with negative controls (P = 0.001; Fig. 3A ). This increase was significantly inhibited by treatment with 3 or 6 mg/kg PD153035 (P = 0.009 and P < 0.001, respectively; Fig. 3A) .
The levels of pEGFR and pSTAT3 were significantly higher in positive controls than in negative controls (P < 0.001; Fig. 3C ). PD153035 treatment (3 or 6 mg/kg) resulted in a decrease of pEGFR and pSTAT3 levels compared with positive controls (P < 0.001 for both PD153035 concentrations; Fig. 3C ).
Discussion
Activation of EGFR and its downstream pathways leads to cell proliferation, migration, adhesion, suppression of apoptosis, angiogenesis and metastasis. 16 More than 95% of head and neck squamous cell carcinomas have been shown to express elevated levels of EGFR. 17, 18 EGFR overexpression in oral cancer has been associated with poor prognosis and is correlated with radioresistance and locoregional failure. 19 In addition, copy number of the gene that encodes for EGFR H Ge, H Liu, Z Fu et al. has been found to predict progression from oral premalignant lesion to OSCC. 20 Inhibition of EGFR and/or its downstream signal transduction pathways presents a promising strategy for the development of chemotherapeutic and chemopreventive agents in OSCC. 21 The EGFR inhibitor, PD153035, has been shown potently and selectively to inhibit EGFR kinase activity by binding reversibly to the inner membrane ATP-binding domain. 13 PD153035 inhibits the tyrosine kinase activity of EGFR at picomolar concentrations and EGFR autophosphorylation in mouse fibroblasts and A431 human epidermoid carcinoma cells at nanomolar concentrations. 11 The present study demonstrated that PD153035 efficiently inhibited the growth of several human cancer cell lines in vitro, in particular KB and KB/V oral cancer cells. This growth inhibition is likely to be mediated by the inhibition of cell cycle progression and an increase in apoptosis. PD153035 had inhibitory effects on KB and KB/V cell-induced tumorigenesis in nude mice, inhibiting the growth of both KB and KB/V tumours at 8 mg/kg, and KB tumours at 4 mg/kg. This difference in inhibitory effect may be due to the different sensitivities of these two cell lines to PD153035 and reflect the presence of mutations in one or more components of the EGFR signalling pathway as well as the use of alternative growth factor signalling pathways, as has been shown in nonsmall cell lung cancer (NSCLC ). 22 -24 The DMBA-induced hamster cheek pouch model was used to evaluate the chemopreventive effect of PD153035. Treatment with PD153035 for 12 weeks reduced the number and volume of visible tumours, as well as the number of dysplasias and OSCCs, but this effect did not appear to be dose-dependent. This is consistent with the finding that PD153035 inhibited the DMBA-induced increase in cell proliferation index in the present study.
EGFR inhibitor treatment of OSCC
Research has indicated that monotherapy with EGFR inhibitors has a response rate of only 5 -15% in advanced OSCC. 25, 26 This 
may be related to the type of EGFR tyrosine kinase inhibitor used and the presence of mutations in the gene encoding for EGFR. Mutant-enriched sequencing is able to determine EGFR mutation status from the serum of patients with unresectable NSCLC. 27 The use of a noninvasive and sensitive method for detecting EGFR mutation status will allow the tailoring of combination treatment modalities including EGFR tyrosine kinase inhibitors, conventional chemotherapy and radiotherapy, and warrants further investigation.
In conclusion, the present study demonstrated that PD153035 has potent chemotherapeutic and chemopreventive effects in OSCC. The mechanism of action is consistent with its activity as a tyrosine kinase inhibitor, and STAT3 phosphorylation may be a surrogate marker for anti-EGFR therapy in OSCC.
